Annual SG&A
$429.68 M
+$29.98 M+7.50%
31 December 2023
Summary:
Amneal Pharmaceuticals annual selling, general & administrative expenses is currently $429.68 million, with the most recent change of +$29.98 million (+7.50%) on 31 December 2023. During the last 3 years, it has risen by +$102.95 million (+31.51%). AMRX annual SG&A is now at all-time high.AMRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$118.69 M
+$2.23 M+1.91%
30 September 2024
Summary:
Amneal Pharmaceuticals quarterly selling, general & administrative expenses is currently $118.69 million, with the most recent change of +$2.23 million (+1.91%) on 30 September 2024. Over the past year, it has increased by +$5.69 million (+5.03%). AMRX quarterly SG&A is now at all-time high.AMRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.22 B
-$184.45 M-9.04%
30 September 2024
Summary:
Amneal Pharmaceuticals TTM selling, general & administrative expenses is currently -$2.22 billion, with the most recent change of -$184.45 million (-9.04%) on 30 September 2024. Over the past year, it has dropped by -$2.65 billion (-625.93%).AMRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AMRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.5% | +5.0% | -625.9% |
| 3 y3 years | +31.5% | +29.9% | -730.0% |
| 5 y5 years | +88.6% | +86.0% | -875.5% |
AMRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +31.5% | at high | +29.9% | -104.0% | at low |
| 5 y | 5 years | at high | +88.6% | at high | +86.0% | -335.0% | at low |
| alltime | all time | at high | +294.0% | at high | +372.5% | -586.9% | at low |
Amneal Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $118.69 M(+1.9%) | $456.75 M(+1.3%) |
| June 2024 | - | $116.46 M(+3.4%) | $451.07 M(+2.5%) |
| Mar 2024 | - | $112.59 M(+3.3%) | $440.17 M(+2.4%) |
| Dec 2023 | $429.68 M(+7.5%) | $109.00 M(-3.5%) | $429.68 M(+1.6%) |
| Sept 2023 | - | $113.01 M(+7.0%) | $422.83 M(+3.2%) |
| June 2023 | - | $105.57 M(+3.4%) | $409.89 M(+1.7%) |
| Mar 2023 | - | $102.10 M(-0.1%) | $403.13 M(+0.9%) |
| Dec 2022 | $399.70 M(+9.4%) | $102.16 M(+2.1%) | $399.70 M(+1.2%) |
| Sept 2022 | - | $100.07 M(+1.3%) | $394.77 M(+2.2%) |
| June 2022 | - | $98.81 M(+0.1%) | $386.09 M(+3.4%) |
| Mar 2022 | - | $98.67 M(+1.5%) | $373.44 M(+2.2%) |
| Dec 2021 | $365.50 M(+11.9%) | $97.22 M(+6.4%) | $365.50 M(+3.6%) |
| Sept 2021 | - | $91.40 M(+6.1%) | $352.97 M(+2.4%) |
| June 2021 | - | $86.16 M(-5.0%) | $344.69 M(+1.5%) |
| Mar 2021 | - | $90.73 M(+7.1%) | $339.48 M(+3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $326.73 M(+12.8%) | $84.69 M(+1.9%) | $326.73 M(+3.4%) |
| Sept 2020 | - | $83.12 M(+2.7%) | $316.12 M(+6.5%) |
| June 2020 | - | $80.94 M(+3.8%) | $296.80 M(+4.8%) |
| Mar 2020 | - | $77.98 M(+5.3%) | $283.14 M(-2.2%) |
| Dec 2019 | $289.60 M(+27.1%) | $74.08 M(+16.1%) | $289.60 M(+1.0%) |
| Sept 2019 | - | $63.80 M(-5.2%) | $286.75 M(-3.9%) |
| June 2019 | - | $67.28 M(-20.3%) | $298.44 M(+3.9%) |
| Mar 2019 | - | $84.44 M(+18.5%) | $287.16 M(+26.0%) |
| Dec 2018 | $227.85 M(+108.9%) | $71.24 M(-5.6%) | $227.85 M(+24.1%) |
| Sept 2018 | - | $75.49 M(+34.8%) | $183.58 M(+35.5%) |
| June 2018 | - | $56.00 M(+122.9%) | $135.53 M(+27.3%) |
| Mar 2018 | - | $25.12 M(-6.8%) | $106.47 M(+30.9%) |
| Dec 2017 | $109.05 M(-8.2%) | $26.97 M(-1.7%) | $81.34 M(+49.6%) |
| Sept 2017 | - | $27.44 M(+1.9%) | $54.38 M(+101.9%) |
| June 2017 | - | $26.94 M | $26.94 M |
| Dec 2016 | $118.76 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual SG&A year-on-year change?
- What is Amneal Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly SG&A year-on-year change?
- What is Amneal Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM SG&A year-on-year change?
What is Amneal Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of AMRX is $429.68 M
What is the all time high annual SG&A for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual selling, general & administrative expenses is $429.68 M
What is Amneal Pharmaceuticals annual SG&A year-on-year change?
Over the past year, AMRX annual selling, general & administrative expenses has changed by +$29.98 M (+7.50%)
What is Amneal Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of AMRX is $118.69 M
What is the all time high quarterly SG&A for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $118.69 M
What is Amneal Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, AMRX quarterly selling, general & administrative expenses has changed by +$5.69 M (+5.03%)
What is Amneal Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of AMRX is -$2.22 B
What is the all time high TTM SG&A for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM selling, general & administrative expenses is $456.75 M
What is Amneal Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, AMRX TTM selling, general & administrative expenses has changed by -$2.65 B (-625.93%)